New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to ...
In the Bax24 study reported at the AHA, aldosterone synthase inhibitor (ASI) baxdrostat achieved a 16.6 mm Hg reduction in 24 ...
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in ...
India Today on MSN
Big hope for resistant hypertension patients
A novel experimental drug may soon change the outlook for patients battling hard-to-treat hypertension. AstraZeneca's ...
Novel Aldosterone Synthase Inhibitor Lorundrostat Shows Promise for Uncontrolled Hypertension in CKD
A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.
Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood ...
For patients with resistant hypertension, a quadruple single pill is superior to triple therapy. HealthDay News — For patients with resistant hypertension, a quadruple single pill is superior to ...
Resistant hypertension affects millions in India, where blood pressure remains high despite multiple medications. A new ...
May 22, 2012 (New York, New York) — An analysis from a large US database of patients with high blood pressure has shown that individuals with resistant hypertension have significantly elevated risks ...
Switzerland’s Idorsia has announced the publication of a new analysis from the landmark Phase III PRECISION study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback